Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GNRHR | P30968 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAT2A | P31153 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13084708 | 1.00 | IDO1 (0.38) | IDO1MAPTNPSR1TP53LMNA | |
| SCHEMBL13036366 | 1.00 | IDO1 (0.38) | IDO1MAPTNPSR1TP53LMNA | |
| SCHEMBL13036414 | 0.91 | TP53 (0.35) | TP53 | |
| SCHEMBL13036415 | 0.91 | TP53 (0.35) | TP53 | |
| SCHEMBL13036380 | 0.90 | TP53 (0.43) | MAPTNPSR1TP53LMNAPOLB | |
| SCHEMBL13036379 | 0.90 | TP53 (0.43) | MAPTNPSR1TP53LMNAPOLB | |
| SCHEMBL13036282 | 0.87 | TACR1 (0.41) | MAPTTHRBALDH1A1RECQLKDM4E | |
| SCHEMBL13084643 | 0.87 | TACR1 (0.41) | MAPTTHRBALDH1A1RECQLKDM4E | |
| SCHEMBL13036285 | 0.87 | TACR1 (0.41) | MAPTTHRBALDH1A1RECQLKDM4E | |
| SCHEMBL13036403 | 0.80 | FFAR1 (0.41) | MAPTNPSR1LMNAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825264-B2 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| US-7825264-B2 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| US-20080188520-A1 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | SANOFI-AVENTIS (FR) | 2008-08-07 | — | — | US | disclosed |
| US-20080188520-A1 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | SANOFI-AVENTIS (FR) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188520-A1 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | KCNH1, MLLT3, CYP1A2 | IDO1 2656/4885MAPT 4766/4885NPSR1 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.